- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:39 | BIOSERGEN AB: Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005 | 1 | Cision News | ||
| Mo | BIOSERGEN AB: Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million | 1 | Cision News | ||
| Mo | The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49 | 1 | Cision News | ||
| 13.11. | BIOSERGEN AB: Biosergen discusses positive results in patients with deadly fungal infections | 2 | Cision News | ||
| 08.11. | Biosergen AB: Biosergen publishes interim report for third quarter 2024 | 50 | GlobeNewswire (Europe) | Friday November 8, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the... ► Artikel lesen | |
| 07.11. | BIOSERGEN AB: Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial | 1 | Cision News | ||
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 06.11. | BIOSERGEN AB: Biosergen's CEO: "I'm optimistic that we may cure patients" | 2 | Cision News | ||
| 31.10. | BIOSERGEN AB: Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections | 1 | Cision News | ||
| 18.10. | BIOSERGEN AB: Biosergen advances BSG005 antifungal drug candidate trial | 1 | Cision News | ||
| 07.10. | Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial | 78 | GlobeNewswire (Europe) | October 7, 2024 - Biosergen AB ("Biosergen"), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first... ► Artikel lesen | |
| 06.09. | BIOSERGEN AB: Biosergen's CEO: "The first patient regained his health" | 1 | Cision News | ||
| 05.09. | Biosergen - Optimism after treatment success - Mangold Insight Analysis | 1 | Cision News | ||
| 30.08. | Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005 | 2 | GlobeNewswire (USA) | ||
| 30.08. | BIOSERGEN AB: Biosergen publishes interim report for second quarter 2024 | 1 | Cision News | ||
| 12.07. | BIOSERGEN AB: First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection | 1 | Cision News | ||
| 14.06. | Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB | 1 | Cision News | ||
| 12.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection | 120 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead... ► Artikel lesen | |
| 12.06. | BIOSERGEN AB: Biosergen to welcome two new board members based on election at the Annual General Meeting | 1 | Cision News | ||
| 11.06. | BIOSERGEN AB: Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection. | 1 | Cision News | ||
| 31.05. | BIOSERGEN AB: Biosergen publishes interim report for first quarter 2024 | 3 | Cision News |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,835 | -0,71 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
| QIAGEN | 40,170 | +3,42 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
BIOSERGEN AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,050 Euro und damit -4,20 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.
